High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. - Wikidata - awgldk - TriplyDB

High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

http://www.wikidata.org/entity/Q33373525

about

Advances in Diagnosis and Treatments for Immune Thrombocytopenia Contemporary management of primary immune thrombocytopenia in adults Piecing together the humoral and cellular mechanisms of immune thrombocytopenia Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection CD16 and CD32 Gene Polymorphisms May Contribute to Risk of Idiopathic Thrombocytopenic Purpura.Gene expression and pathway analysis of immune thrombocytopenic purpura.BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.The ITP syndrome: pathogenic and clinical diversity.Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications.Genetic studies in pediatric ITP: outlook, feasibility, and requirements.Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients.ITP: a historical perspective.Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura.Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP).Defective regulatory B-cell compartment in patients with immune thrombocytopenia Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions.Cellular immune dysfunction in immune thrombocytopenia (ITP).Oxidative stress is predominant in female but not in male patients with autoimmune thrombocytopenia.Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines.Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia.CD86 +1057G/A polymorphism and risk of chronic immune thrombocytopenia.Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)Emerging drugs for immune thrombocytopenia (ITP).Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases.High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency.BAFF is increased in renal transplant patients following treatment with alemtuzumab Manipulating B cell homeostasis: a key component in the advancement of targeted strategies Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia.Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.B-cell biomarkers in transplantation--from genes to therapy.A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia.

P2860

Q26738630-1ACE5D6A-5CC4-4817-8F20-5797DA03D694 Q26853680-A7712C46-C7D2-442D-935F-4CC4F5615C49 Q27024841-7F63FE54-05F8-4B1F-948B-CAAFB7E44624 Q28294329-6CF11EED-B3D1-446F-A6CF-8D2DEB07050F Q30249541-E138A286-2709-40F0-8E5A-0361AB1208BA Q33377373-59F91E83-049C-4B5A-88FE-45E22B853E24 Q33381985-1B5AF109-7505-4560-A00C-53C7F2DAD635 Q33384235-5B61F789-9200-4278-9ACF-E9DC3700368A Q33386608-35D22F9B-737B-41DE-8BE7-E12597240416 Q33388868-A623FDD7-C725-44F8-A4DE-B8C818C2D73C Q33390753-436EBF34-F5A8-4BC4-BB19-F8E2B2699735 Q33394791-B6039FEF-0EFA-447F-8489-FADAA447843E Q33395384-B3CAE7F4-45DD-4F8F-A54F-F15486E1FB7C Q33396043-3FC964BD-22BB-4A80-B6A7-E1CD10C6460D Q33402659-17AFB4FD-80AD-4F75-9DB9-1EBDE2E00456 Q33404315-4375CA0E-00BE-4588-88C5-AC204F7F175F Q33409710-5AFDC52E-4390-43B8-AE3E-7543EF209E03 Q33414364-851250A4-6CFD-4430-AF7F-0932FF544CA8 Q33414858-E096A3D5-4134-4474-A16E-C9A0CC041336 Q33415681-367E3589-F345-42A7-B0B1-1BDD991F0553 Q33415735-6C81B3D7-698F-45CB-A300-7EE3115BC704 Q33418883-5C02A226-92B5-4BFB-812B-A26FE400AF76 Q33426961-9ACA2294-5A10-4AE2-9982-2E17B39E8F36 Q33428073-C525B53C-19D7-4A0A-A14F-838367043D0B Q33430058-519858AA-DBB4-44DD-AFF6-28E5C7F5564A Q33430662-74642DD3-A249-4482-8EF0-2E2E7C46DB90 Q33439412-EDC7DA47-67BD-4061-8F58-3A2F3D9F6F86 Q33439789-FFD88AD5-2109-4045-AF2E-8843F4FDE5B8 Q34743817-743973B4-D576-4B84-B97D-E260BBDBDC16 Q36005239-7EFCF7EC-ACFF-48FE-B603-87032CD0661F Q36800138-BAEAE442-457C-4CFE-8B24-CDC963BE9F51 Q36925946-B657113C-4CDF-4040-BA8C-7921580B0524 Q37177128-50B8AB48-1A12-49B2-BD9B-2186C05D5D57 Q37345560-851CDCB7-8D1D-480A-91C4-DAD597E627E8 Q37350904-59081960-39CE-42F9-9D28-4249FA22AEEF Q37396032-9E84405F-2328-4231-8DDD-896A3FA3840C Q37638789-11B9E784-14AF-468B-95F8-E8F281FAC7C3 Q37686026-E40AD64C-7357-4535-B623-B62DE5CF2927 Q38334458-A60EF57B-3B49-4D7A-8468-4A69AF9A2E6F Q40073655-FFBBDABE-BC61-4E8E-90AE-59E8AC1A4D5D

P2860

High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

http://www.wikidata.org/entity/Q33373525

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@ast

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@en

type

label

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@ast

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@en

prefLabel

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@ast

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@en

P1433

Q33373525-D710AEC5-1D82-4D3D-8E5F-3E7438F3705F

P1476

Q33373525-9AE42D73-9452-4DC3-8B97-4E8F8762EC71

P2093

Q33373525-08952F04-3927-412C-8A93-56685127B581

Q33373525-12EF83CE-1287-4051-A469-FDA62D730B1C

Q33373525-1F196B44-9E24-45F9-BC26-54981520FB3E

Q33373525-1F2856E0-96F4-4C31-A5D3-C8BFA10E7E8E

Q33373525-6E957233-DD17-4931-B6ED-A2F83C4E8A3E

Q33373525-85FA70A8-ED78-48B7-847A-266CDBE97700

Q33373525-AAB61CAC-96CA-40CC-8ABA-759F626ADC10

P2860

Q33373525-023F1F9A-7E97-4254-BAD3-09781445121B

Q33373525-06C1800E-6312-47BA-B4F2-83D24E51AC1D

Q33373525-0E137909-31A5-4D42-ABAE-AA20353F3FEF

Q33373525-14A43FE7-F6D7-4134-820C-5C35EA163C12

Q33373525-2FB95258-C8EF-4658-8FDC-DE1543BD32A8

Q33373525-3405EF12-5575-4CC0-87C7-37B731824E44

Q33373525-3652678E-11E3-4CE8-AB1B-4C04015E6895

Q33373525-42148695-9603-40EC-91D9-2408D5BFAFB1

Q33373525-4DFBA970-F8E3-440D-8432-EAB7220356E6

Q33373525-728977BB-C9C9-4F85-8F18-916AD9025D1F

P304

Q33373525-35F10E3B-C120-46FE-B3B7-FA65F2446069

P31

Q33373525-E568E500-7BC0-4CCC-A080-3DE4E89A55D6

P356

Q33373525-D07C0094-C84B-48E0-8A9B-4421C0B60849

P407

Q33373525-A7498773-25D3-40DF-B221-36D0DDBE733C

P433

Q33373525-106AA8C6-DE8D-4A9E-A4B7-04F0BF4F37BD

P478

Q33373525-AAB80109-E4F1-4C60-8535-A47AF74EA387

P50

Q33373525-00E9BA51-C10A-49CC-94C6-2A0324F186CA

P577

Q33373525-FD608596-D3EA-4A35-BFAE-F9CB9EC70C7D

P5875

Q33373525-6B1278C7-A644-475D-9234-73EA5387EF62

P698

Q33373525-B3C032F2-F6BC-452F-A889-F68966D5D08D

P921

Q33373525-AFC7BAAC-C251-40FA-B5BD-62C6F06A8959

P356

J.1365-2141.2006.06431.X

P1433

British Journal of Haematology

P1476

High-level serum B-cell activa ...... thic thrombocytopenic purpura.

@en

P2093

Abdulgabar Salama

http://www.w3.org/2001/XMLSchema#string

Alaa Barakat

http://www.w3.org/2001/XMLSchema#string

Caroline Mühle

http://www.w3.org/2001/XMLSchema#string

Florian Emmerich

http://www.w3.org/2001/XMLSchema#string

Julian Milz

http://www.w3.org/2001/XMLSchema#string

Lorena Martinez-Gamboa

http://www.w3.org/2001/XMLSchema#string

Thomas Dörner

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

The current status of targeting BAFF/BLyS for autoimmune diseases

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

BCMA is essential for the survival of long-lived bone marrow plasma cells

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.

Immune thrombocytopenic purpura.

Management of patients with refractory immune thrombocytopenic purpura.

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.

P304

309-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2006.06431.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6643911

http://www.w3.org/2001/XMLSchema#string

P698

17156395

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia